Feinstein Institute Chemist Receives Prestigious Award for Alzheimer's Drug Research
| The Feinstein Institute for Medical Research announced today that Yousef Al-Abed, PhD, director of the Institute’s Laboratory of Medical Chemistry, is a recipient of the Alzheimer's Drug Discovery Foundation’s (ADDF) second annual research award -- Novel Approaches to Drug Discovery for Alzheimer's Disease. Six recipients were selected from a highly competitive pool of 32 scientists from six countries. The ADDF is a biomedical philanthropy venture founded by the Estee Lauder family, and Elan Pharmaceuticals, Inc., a neuroscience-based biotechnology company. The recipients were chosen by an independent scientific review panel of 10 experts chaired by ADDF Executive Director Howard Fillit, MD, a leading geriatrician and neuroscientist. "These awardees are conducting innovative research in Alzheimer's drug discovery. Their programs were recognized as most promising to advance the discovery of effective disease-modifying drugs for Alzheimer's,” said Dr. Fillet. “Thanks to our collaboration with Elan, we are delighted to present grant awards totaling $520,000 for this year's program."
About the Alzheimer's Drug Discovery Foundation (ADDF) About The Feinstein Institute for Medical Research Media Contact: Public Relations 516-465-2600 |
